Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects
Objective: Pharmacokinetics (PK), pharmacodynamics (PD), safety and immunogenicity studies were conducted to evaluate the bioequivalence of CMAB807, a biosimilar to denosumab (Prolia®), which is the only approved RANKL inhibitor for the treatment of osteoporosis.Methods: In this randomized, double-b...
Сохранить в:
| Главные авторы: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Frontiers Media S.A.
2022-01-01
|
| Серии: | Frontiers in Pharmacology |
| Предметы: | |
| Online-ссылка: | https://www.frontiersin.org/articles/10.3389/fphar.2022.821944/full |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|